logo-loader
HealthPharma & Biotech
e-Therapeutics plc

e-Therapeutics appoints Amgen heavy-hitter as new CEO

Dr Raymond Barlow brings with him a “broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector”, ETX said.

empt_boardroom,_sized_58733c2b175fe.png
There will be a new face around the boardroom table

e-Therapeutics PLC (LON:ETX) said it has successfully concluded its search for a new chief executive.

He is Dr Raymond Barlow, currently executive director of corporate development at Amgen, based in Switzerland.

The 48-year-old will join the AIM-listed drug discovery group on or before May 1.

He will take over day to day running of the company from Iain Ross, who is currently executive chairman of e-Therapeutics and fills the role vacated by Professor Malcolm Young, who stepped down last summer.

Barlow brings with him a “broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector”, ETX said.

His previous responsibilities have included scientific, business and corporate roles with AstraZeneca, Crucell and Johnson & Johnson.

Chairman Ross said of the new chief executive: “He joins the company at an exciting time and is a consummate business professional who brings a wealth of relevant experience from the international pharmaceutical and biotech sector.

“I am confident that, as CEO, he will lead us through the next stage of the company's development and achieve both our short and long term goals.”

Quick facts: e-Therapeutics plc

Price: £0.03

Market: AIM
Market Cap: £8.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read